{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:20:10Z","timestamp":1789586410803,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Based on promising results in preclinical models, clinical trials have been performed to evaluate the efficacy of the first-in-class proteasome inhibitor bortezomib towards malignant pleural mesothelioma (MPM), an aggressive cancer arising from the mesothelium of the serous cavities following exposure to asbestos. Unexpectedly, only minimal therapeutic benefits were observed, thus implicating that MPM harbors inherent resistance mechanisms. Identifying the molecular bases of this primary resistance is crucial to develop novel pharmacologic strategies aimed at increasing the vulnerability of MPM to bortezomib. Therefore, we assessed a panel of four human MPM lines with different sensitivity to bortezomib, for functional proteasome activity and levels of free and polymerized ubiquitin. We found that highly sensitive MPM lines display lower proteasome activity than more bortezomib-resistant clones, suggesting that reduced proteasomal capacity might contribute to the intrinsic susceptibility of mesothelioma cells to proteasome inhibitors-induced apoptosis. Moreover, MPM equipped with fewer active proteasomes accumulated polyubiquitinated proteins, at the expense of free ubiquitin, a condition known as proteasome stress, which lowers the cellular apoptotic threshold and sensitizes mesothelioma cells to bortezomib-induced toxicity as shown herein. Taken together, our data suggest that an unfavorable load-versus-capacity balance represents a critical determinant of primary apoptotic sensitivity to bortezomib in MPM.<\/jats:p>","DOI":"10.1038\/s41598-017-17977-9","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T10:27:44Z","timestamp":1512988064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis"],"prefix":"10.1038","volume":"7","author":[{"given":"Fulvia","family":"Cerruti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genny","family":"Jocoll\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Salio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Paglietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Alessandria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mioletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmauro","family":"Numico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-7518","authenticated-orcid":false,"given":"Simone","family":"Cenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"17977_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","volume":"68","author":"D Voges","year":"1999","unstructured":"Voges, D., Zwickl, P. & Baumeister, W. The Ubiquitin 26S Proteasome Proteolytic Pathway. Annu. Rev. Biochem. \n                           68, 1015\u20131068 (1999).","journal-title":"Annu. Rev. Biochem."},{"key":"17977_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0092-8674(00)80929-0","volume":"92","author":"W Baumeister","year":"1998","unstructured":"Baumeister, W., Walz, J., Z\u00fchl, F. & Seem\u00fcller, E. The proteasome: Paradigm of a self-compartmentalizing protease. Cell \n                           92, 367\u2013380 (1998).","journal-title":"Cell"},{"key":"17977_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1146\/annurev.bi.65.070196.004101","volume":"65","author":"O Coux","year":"1996","unstructured":"Coux, O., Tanaka, K. & Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. \n                           65, 801\u2013847 (1996).","journal-title":"Annu. Rev. Biochem."},{"key":"17977_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/biom4020566","volume":"4","author":"P Cascio","year":"2014","unstructured":"Cascio, P. PA28\u03b1\u03b2: The Enigmatic Magic Ring of the Proteasome? Biomolecules \n                           4, 566\u201384 (2014).","journal-title":"Biomolecules"},{"key":"17977_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.chembiol.2014.02.006","volume":"21","author":"M Raule","year":"2014","unstructured":"Raule, M. et al. PA28\u03b1\u03b2 reduces size and increases hydrophilicity of 20S immunoproteasome peptide products. Chem. & Biol. \n                           21, 470\u2013480 (2014).","journal-title":"Chem. & Biol."},{"key":"17977_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","volume":"8","author":"AF Kisselev","year":"2001","unstructured":"Kisselev, A. F. & Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. & Biol. \n                           8, 739\u2013758 (2001).","journal-title":"Chem. & Biol."},{"key":"17977_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","volume":"5","author":"J Adams","year":"2004","unstructured":"Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell \n                           5, 417\u2013421 (2004).","journal-title":"Cancer Cell"},{"key":"17977_CR8","first-page":"4342","volume":"58","author":"RZ Orlowski","year":"1998","unstructured":"Orlowski, R. Z. et al. Tumor growth inhibition induced in a murine model of human Burkitt\u2019s lymphoma by a proteasome inhibitor. Cancer Res. \n                           58, 4342\u20134348 (1998).","journal-title":"Cancer Res."},{"key":"17977_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. \n                           359, 906\u2013917 (2008).","journal-title":"N. Engl. J. Med."},{"key":"17977_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor, O. A. et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J. Clin. Oncol. \n                           23, 676\u2013684 (2005).","journal-title":"J. Clin. Oncol."},{"key":"17977_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","volume":"19","author":"AF Kisselev","year":"2012","unstructured":"Kisselev, A. F., Van Der Linden, W. A. & Overkleeft, H. S. Proteasome inhibitors: An expanding army attacking a unique target. Chem. & Biol. \n                           19, 99\u2013115 (2012).","journal-title":"Chem. & Biol."},{"key":"17977_CR12","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"RZ Orlowski","year":"2008","unstructured":"Orlowski, R. Z. & Kuhn, D. J. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin. Cancer Res. \n                           14, 1649\u20131657 (2008).","journal-title":"Clin. Cancer Res."},{"key":"17977_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1078-0432.CCR-11-0853","volume":"18","author":"SM Molineaux","year":"2012","unstructured":"Molineaux, S. M. Molecular pathways: Targeting proteasomal protein degradation in cancer. Clin. Cancer Res. \n                           18, 15\u201320 (2012).","journal-title":"Clin. Cancer Res."},{"key":"17977_CR14","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/leu.2009.173","volume":"23","author":"JJ Shah","year":"2009","unstructured":"Shah, J. J. & Orlowski, R. Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia \n                           23, 1964\u20131979 (2009).","journal-title":"Leukemia"},{"key":"17977_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1053\/j.seminhematol.2012.04.006","volume":"49","author":"T Hideshima","year":"2012","unstructured":"Hideshima, T. & Anderson, K. C. Biologic Impact of Proteasome Inhibition in Multiple Myeloma Cells-From the Aspects of Preclinical Studies. Semin. Hematol. \n                           49, 223\u2013227 (2012).","journal-title":"Semin. Hematol."},{"key":"17977_CR16","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/j.1471-4159.2004.02813.x","volume":"91","author":"CS Lee","year":"2004","unstructured":"Lee, C. S. et al. A proteasomal stress response: Pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury. J. Neurochem. \n                           91, 996\u20131006 (2004).","journal-title":"J. Neurochem."},{"key":"17977_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.febslet.2004.04.078","volume":"567","author":"MK London","year":"2004","unstructured":"London, M. K., Keck, B. I., Ramos, P. C. & Dohmen, R. J. Regulatory mechanisms controlling biogenesis of ubiquitin and the proteasome. FEBS Lett. \n                           567, 259\u2013264 (2004).","journal-title":"FEBS Lett."},{"key":"17977_CR18","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","volume":"113","author":"G Bianchi","year":"2009","unstructured":"Bianchi, G. et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood \n                           113, 3040\u20133049 (2009).","journal-title":"Blood"},{"key":"17977_CR19","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/eji.200737743","volume":"38","author":"P Cascio","year":"2008","unstructured":"Cascio, P. et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur. J. Immunol. \n                           38, 658\u2013667 (2008).","journal-title":"Eur. J. Immunol."},{"key":"17977_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/sj.emboj.7601009","volume":"25","author":"S Cenci","year":"2006","unstructured":"Cenci, S. et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. \n                           25, 1104\u20131113 (2006).","journal-title":"EMBO J."},{"key":"17977_CR21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1189\/jlb.1011497","volume":"92","author":"S Cenci","year":"2012","unstructured":"Cenci, S. et al. Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J. Leukoc. Biol. \n                           92, 921\u2013931 (2012).","journal-title":"J. Leukoc. Biol."},{"key":"17977_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.trsl.2009.01.004","volume":"153","author":"DW Kamp","year":"2009","unstructured":"Kamp, D. W. Asbestos-induced lung diseases: an update. Translational Research \n                           153, 143\u2013152 (2009).","journal-title":"Translational Research"},{"key":"17977_CR23","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1056\/NEJMra050152","volume":"353","author":"BWS Robinson","year":"2005","unstructured":"Robinson, B. W. S. & Lake, R. A. Advances in Malignant Mesothelioma. N. Engl. J. Med. \n                           353, 1591\u20131603 (2005).","journal-title":"N. Engl. J. Med."},{"key":"17977_CR24","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","volume":"27","author":"AS Tsao","year":"2009","unstructured":"Tsao, A. S., Wistuba, I., Roth, J. A. & Kindler, H. L. Malignant pleural mesothelioma. J. Clin. Oncol. \n                           27, 2081\u20132090 (2009).","journal-title":"J. Clin. Oncol."},{"key":"17977_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/icvts\/ivs542","volume":"16","author":"SM Gelvez-Zapata","year":"2013","unstructured":"Gelvez-Zapata, S. M., Gaffney, D., Scarci, M. & Coonar, A. S. What is the survival after surgery for localized malignant pleural mesothelioma? Interact. Cardiovasc. Thorac. Surg. \n                           16, 533\u2013537 (2013).","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"17977_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncponc1039","volume":"5","author":"Da Fennell","year":"2008","unstructured":"Fennell, Da, Gaudino, G., O\u2019Byrne, K. J., Mutti, L. & van Meerbeeck, J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat. Clin. Pract. Oncol. \n                           5, 136\u2013147 (2008).","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"17977_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11912-005-0048-3","volume":"7","author":"RK Goudar","year":"2005","unstructured":"Goudar, R. K. New therapeutic options for mesothelioma. Curr. Oncol. Rep. \n                           7, 260\u2013265 (2005).","journal-title":"Curr. Oncol. Rep."},{"key":"17977_CR28","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. \n                           21, 2636\u20132644 (2003).","journal-title":"J. Clin. Oncol."},{"key":"17977_CR29","doi-asserted-by":"crossref","unstructured":"Zalcman, G., Brosseau, S. & Scherpereel, A. Prophylactic radiotherapy to prevent procedure-tract metastases. Lancet Oncol. 17 (2016).","DOI":"10.1016\/S1470-2045(16)30387-4"},{"key":"17977_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.hoc.2005.09.010","volume":"19","author":"LM Krug","year":"2005","unstructured":"Krug, L. M. An overview of chemotherapy for mesothelioma. Hematology\/Oncology Clinics of North America \n                           19, 1117\u20131136 (2005).","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"17977_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2009.03.016","volume":"67","author":"OD R\u00f8e","year":"2010","unstructured":"R\u00f8e, O. D. et al. Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer \n                           67, 57\u201368 (2010).","journal-title":"Lung Cancer"},{"key":"17977_CR32","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/sj.onc.1209809","volume":"26","author":"AC Borczuk","year":"2007","unstructured":"Borczuk, A. C. et al. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene \n                           26, 610\u2013617 (2007).","journal-title":"Oncogene"},{"key":"17977_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. \n                           43, 668\u2013672 (2011).","journal-title":"Nat. Genet."},{"key":"17977_CR34","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/1078-0432.CCR-0607-3","volume":"10","author":"HI Pass","year":"2004","unstructured":"Pass, H. I. et al. Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma. Clin. Cancer Res. \n                           10, 849\u2013859 (2004).","journal-title":"Clin. Cancer Res."},{"key":"17977_CR35","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","volume":"166","author":"GJ Gordon","year":"2005","unstructured":"Gordon, G. J. et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am. J. Pathol. \n                           166, 1827\u201340 (2005).","journal-title":"Am. J. Pathol."},{"key":"17977_CR36","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","volume":"66","author":"F L\u00f3pez-R\u00edos","year":"2006","unstructured":"L\u00f3pez-R\u00edos, F. et al. Global gene expression profiling of pleural mesotheliomas: Overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. \n                           66, 2970\u20132979 (2006).","journal-title":"Cancer Res."},{"key":"17977_CR37","doi-asserted-by":"crossref","unstructured":"R\u00f8e, O. D. et al. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: The emerging gene portrait of the mesothelioma phenotype. PLoS One \n                           4 (2009).","DOI":"10.1371\/journal.pone.0006554"},{"key":"17977_CR38","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","volume":"20","author":"A de Reyni\u00e8s","year":"2014","unstructured":"de Reyni\u00e8s, A. et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin. Cancer Res. \n                           20, 1323\u201334 (2014).","journal-title":"Clin. Cancer Res."},{"key":"17977_CR39","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. \n                           48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"17977_CR40","doi-asserted-by":"publisher","unstructured":"Quispel-Janssen, J. M. et al. Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition. Clin. Cancer Res. 23, https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1172 (2017).","DOI":"10.1158\/1078-0432.CCR-17-1172"},{"key":"17977_CR41","doi-asserted-by":"publisher","unstructured":"Schunselaar, L. et al. Chemical profiling of primary mesothelioma cultures defines subtypes with different expression profiles and clinical responses. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1345 (2017).","DOI":"10.1158\/1078-0432.CCR-17-1345"},{"key":"17977_CR42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00280-009-1181-8","volume":"66","author":"Y Wang","year":"2010","unstructured":"Wang, Y. et al. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother. Pharmacol. \n                           66, 455\u2013466 (2010).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"17977_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00280-007-0500-1","volume":"61","author":"GJ Gordon","year":"2008","unstructured":"Gordon, G. J. et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother. Pharmacol. \n                           61, 549\u2013558 (2008).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"17977_CR44","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-07-0536","volume":"13","author":"A Sartore-Bianchi","year":"2007","unstructured":"Sartore-Bianchi, A. et al. Bortezomib inhibits nuclear factor-kappaB-dependent survival and has potent in vivo activity in mesothelioma. Clin. Cancer Res. \n                           13, 5942\u20135951 (2007).","journal-title":"Clin. Cancer Res."},{"key":"17977_CR45","doi-asserted-by":"crossref","unstructured":"Busacca, S. et al. BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma. PLoS One \n                           8 (2013).","DOI":"10.1371\/annotation\/90879c69-ebc5-40b2-9926-4a00e4f9e055"},{"key":"17977_CR46","doi-asserted-by":"publisher","first-page":"13021","DOI":"10.1074\/jbc.M709698200","volume":"283","author":"D Barbone","year":"2008","unstructured":"Barbone, D., Yang, T. M., Morgan, J. R., Gaudino, G. & Broaddus, V. C. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J. Biol. Chem. \n                           283, 13021\u201313030 (2008).","journal-title":"J. Biol. Chem."},{"key":"17977_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.58","volume":"2","author":"D Barbone","year":"2011","unstructured":"Barbone, D. et al. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis. \n                           2, e174 (2011).","journal-title":"Cell Death Dis."},{"key":"17977_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-140","volume":"13","author":"B-Z Yuan","year":"2013","unstructured":"Yuan, B.-Z. et al. TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages. BMC Cancer \n                           13, 140 (2013).","journal-title":"BMC Cancer"},{"key":"17977_CR49","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","volume":"7","author":"Da Fennell","year":"2012","unstructured":"Fennell, Da et al. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J. Thorac. Oncol. \n                           7, 1466\u20131470 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"17977_CR50","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, M. et al. Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052. J. Clin. Oncol. 30 (2012).","DOI":"10.1200\/jco.2012.30.15_suppl.7081"},{"key":"17977_CR51","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0076-6879(05)98030-0","volume":"398","author":"AF Kisselev","year":"2005","unstructured":"Kisselev, A. F. & Goldberg, A. L. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol. \n                           398, 364\u2013378 (2005).","journal-title":"Methods Enzymol."},{"key":"17977_CR52","doi-asserted-by":"publisher","first-page":"25200","DOI":"10.1074\/jbc.272.40.25200","volume":"272","author":"W Heinemeyer","year":"1997","unstructured":"Heinemeyer, W., Fischer, M., Krimmer, T., Stachon, U. & Wolf, D. H. The active sites of the eukaryotic 20S proteasome and their involvement in subunit precursor processing. J. Biol. Chem. \n                           272, 25200\u201325209 (1997).","journal-title":"J. Biol. Chem."},{"key":"17977_CR53","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.bbamcr.2014.05.005","volume":"1843","author":"M Raule","year":"2014","unstructured":"Raule, M., Cerruti, F. & Cascio, P. Enhanced rate of degradation of basic proteins by 26S immunoproteasomes. Biochim. Biophys. Acta - Mol. Cell Res. \n                           1843, 1942\u20131947 (2014).","journal-title":"Biochim. Biophys. Acta - Mol. Cell Res."},{"key":"17977_CR54","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1096\/fasebj.11.14.9409542","volume":"11","author":"M Schmidt","year":"1997","unstructured":"Schmidt, M. & Kloetzel, P. M. Biogenesis of eukaryotic 20S proteasomes: the complex maturation pathway of a complex enzyme. FASEB J. \n                           11, 1235\u20131243 (1997).","journal-title":"FASEB J."},{"key":"17977_CR55","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ab.2013.05.020","volume":"440","author":"P Schwertman","year":"2013","unstructured":"Schwertman, P. et al. An immunoaffinity purification method for the proteomic analysis of ubiquitinated protein complexes. Anal. Biochem. \n                           440, 227\u2013236 (2013).","journal-title":"Anal. Biochem."},{"key":"17977_CR56","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1007\/s00018-016-2255-5","volume":"73","author":"GL Grice","year":"2016","unstructured":"Grice, G. L. & Nathan, J. A. The recognition of ubiquitinated proteins by the proteasome. Cellular and Molecular Life Sciences \n                           73, 3497\u20133506 (2016).","journal-title":"Cellular and Molecular Life Sciences"},{"key":"17977_CR57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cell.2009.01.041","volume":"137","author":"P Xu","year":"2009","unstructured":"Xu, P. et al. Quantitative Proteomics Reveals the Function of Unconventional Ubiquitin Chains in Proteasomal Degradation. Cell \n                           137, 133\u2013145 (2009).","journal-title":"Cell"},{"key":"17977_CR58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2005.02.022","volume":"232","author":"X Sun","year":"2006","unstructured":"Sun, X., Guly\u00e1s, M., Hjerpe, A. & Dobra, K. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett. \n                           232, 161\u2013169 (2006).","journal-title":"Cancer Lett."},{"key":"17977_CR59","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1593\/tlo.08133","volume":"1","author":"BZ Yuan","year":"2008","unstructured":"Yuan, B. Z., Chapman, J. A. & Reynolds, S. H. Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells. Transl. Oncol. \n                           1, 129\u2013140 (2008).","journal-title":"Transl. Oncol."},{"key":"17977_CR60","doi-asserted-by":"crossref","unstructured":"Shabaneh, T. B. et al. Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib. PLoS One \n                           8 (2013).","DOI":"10.1371\/journal.pone.0056132"},{"key":"17977_CR61","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nature18943","volume":"536","author":"A Rousseau","year":"2016","unstructured":"Rousseau, A. & Bertolotti, A. An evolutionarily conserved pathway controls proteasome homeostasis. Nature \n                           536, 184\u2013189 (2016).","journal-title":"Nature"},{"key":"17977_CR62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molcel.2010.02.029","volume":"38","author":"SK Radhakrishnan","year":"2010","unstructured":"Radhakrishnan, S. K. et al. Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells. Mol. Cell \n                           38, 17\u201328 (2010).","journal-title":"Mol. Cell"},{"key":"17977_CR63","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","volume":"136","author":"J Luo","year":"2009","unstructured":"Luo, J., Solimini, N. L. & Elledge, S. J. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. Cell \n                           136, 823\u2013837 (2009).","journal-title":"Cell"},{"key":"17977_CR64","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1042\/BJ20100383","volume":"430","author":"C Blackburn","year":"2010","unstructured":"Blackburn, C. et al. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S \u03b25-subunit. Biochem. J. \n                           430, 461\u2013476 (2010).","journal-title":"Biochem. J."},{"key":"17977_CR65","doi-asserted-by":"publisher","first-page":"E3454","DOI":"10.1073\/pnas.1213640109","volume":"109","author":"AM Ruschak","year":"2012","unstructured":"Ruschak, A. M. & Kay, L. E. Proteasome allostery as a population shift between interchanging conformers. Proc. Natl. Acad. Sci. \n                           109, E3454\u2013E3462 (2012).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"17977_CR66","doi-asserted-by":"publisher","first-page":"35869","DOI":"10.1074\/jbc.M303725200","volume":"278","author":"AF Kisselev","year":"2003","unstructured":"Kisselev, A. F. et al. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J. Biol. Chem. \n                           278, 35869\u201335877 (2003).","journal-title":"J. Biol. Chem."},{"key":"17977_CR67","doi-asserted-by":"publisher","first-page":"18599","DOI":"10.1073\/pnas.1009778107","volume":"107","author":"B Guillaume","year":"2010","unstructured":"Guillaume, B. et al. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class Imolecules. Proc. Natl. Acad. Sci. \n                           107, 18599\u201318604 (2010).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"17977_CR68","doi-asserted-by":"crossref","unstructured":"Barbone, D. et al. Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression. PLoS One \n                           7 (2012).","DOI":"10.1371\/journal.pone.0052753"},{"key":"17977_CR69","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/35008096","volume":"404","author":"U Schubert","year":"2000","unstructured":"Schubert, U. et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature \n                           404, 770\u2013774 (2000).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17977-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17977-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17977-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T16:26:54Z","timestamp":1671812814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17977-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["17977"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-17977-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,15]]},"assertion":[{"value":"20 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17626"}}